RxDoctor Payments DataLook up a doctor →

Maria Berrocal Fernandez, MD

Ophthalmology · San Juan, PRNPI 1104800630

Payments from drug & device makers

$547,141in general payments, 2019–2025

Across 341 payments — averaging $1604.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$231K
  • Alcon$230K
  • Alcon Research LLC$39K
  • AbbVie$28K
  • Oculus Surgical Inc.$5K
  • Neurotech Pharmaceuticals, Inc.$4K
  • plus $9K from 14 others
$94,650in research payments, 2019–2025

Across 2 payments — averaging $47,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$95K

What the payments were for

  • Consulting fees$325,14659%
  • Speaking & faculty fees$175,05032%
  • Travel & lodging$33,9136%
  • Food & beverage$12,8472%
  • Education$1760%
  • Gifts$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$547,141 in reported general payments places this provider in the 95th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$206,582
Medicare patients
287
Services billed
1,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost84$27,549
Prednisolone Acetate605$22,939
RestasisCyclosporine34$19,416
Brimonidine Tartrate114$10,324
Ofloxacin429$9,950
Alphagan PBrimonidine Tartrate35$9,596
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$9,236
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat229$7,752
Cyclosporine33$7,283
CombiganBrimonidine Tartrate/Timolol23$6,897
AzoptBrinzolamide16$5,797
ErythromycinErythromycin Base306$4,737
Dorzolamide Hcl130$4,296
Latanoprost265$3,916
Fluorometholone51$3,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$27,743$63,459176 claims
AlconAzopt$230,212$5,79716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →